Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian cohort.

Health Research

Text available via DOI:

https://doi.org/10.1111/j.1755-5922.2011.00291.x
Final published version

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian cohort. / Ademi, Zanfina ; Liew, Danny; Hollingsworth, Bruce et al.
In: Cardiovascular Therapeutics, Vol. 31, No. 1, 2013, p. 45-52 .

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Bibtex

@article{09478657e91c4225ac2b2de2b4333194,

title = "Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian cohort.",

author = "Zanfina Ademi and Danny Liew and Bruce Hollingsworth and Steg, {Phillipe Gabriel}",

year = "2013",

doi = "10.1111/j.1755-5922.2011.00291.x",

language = "English",

volume = "31",

pages = "45--52 ",

journal = "Cardiovascular Therapeutics",

issn = "1755-5914",

publisher = "Wiley-Blackwell",

number = "1",

}

RIS

TY - JOUR

T1 - Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian cohort.

AU - Ademi, Zanfina

AU - Liew, Danny

AU - Hollingsworth, Bruce

AU - Steg, Phillipe Gabriel

PY - 2013

Y1 - 2013

U2 - 10.1111/j.1755-5922.2011.00291.x

DO - 10.1111/j.1755-5922.2011.00291.x

M3 - Journal article

VL - 31

SP - 45

EP - 52

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 1

ER -

Research

Text available via DOI: